arrow
P

Péter Reményi

central hospital of southern pest
H指数:15
被引数:812

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adoptive T-cell therapies for persistent COVID-19 in immunocompromised patients: Comparison of IFN-γ virus-specific T-cell therapy and CD45RA+ T-cell depleted donor lymphocyte infusion

免疫缺陷患者持续性COVID-19的过继T细胞疗法:IFN-γ病毒特异性T细胞疗法与CD45RA+ T细胞耗竭的供者淋巴细胞输注的比较

2026-01-120
OAAI
Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation

添加抗胸腺细胞球蛋白对异基因移植后环磷酰胺的影响(与外周血相比):与单独使用异基因移植后环磷酰胺相比的影响:代表欧洲血液与骨髓移植学会细胞治疗与免疫生物学工作组进行的一项回顾性研究

2025-08-070
OAAI
Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT

Allo-hct前使用酪氨酸激酶抑制剂 (伊马替尼或达沙替尼) 的类型对费城阳性急性淋巴细胞白血病患者预后的影响。EBMT急性白血病工作组代表的研究

2025-01-010
PRE
Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

自体造血干细胞移植在自然杀伤/T细胞淋巴瘤中的应用:EBMT淋巴瘤工作组的一项回顾性分析

BLOOD
IF23.1
2024-11-050
PRE
Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT
2023-10-014
OAAI
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (16, 58, 2023)
2023-09-290
OAAI
Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party
2023-08-213
PRE
Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review
2023-07-064
OAAI
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

在首次完全缓解期的继发性与原发性急性髓系白血病患者中,采用移植后环磷酰胺治疗的非T细胞耗竭型单倍体相合造血干细胞移植:一项来自ALWP/EBMT的研究

2023-05-297
OAAI
Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups
2023-03-2711
OAAI
Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
2023-03-013
OAAI
Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT
CANCER
IF5.1
2022-09-152
PRE
Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

多发性骨髓瘤自体干细胞移植的并发症: CALM研究的结果

2022-06-208
OAAI
Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study

冠状病毒疾病2019 (新型冠状病毒肺炎) 入院时补体水平反映严重急性肾损伤 (AKI) 进展: 一项多中心前瞻性队列研究

2022-04-296
OAAI
Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality
2022-01-2116
OAAI
Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection
2021-03-2594
OAAI
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
2021-02-023
OAAI
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT

成人急性淋巴细胞白血病的清髓性同种异体移植中可测量的残留疾病: EBMT急性白血病工作组2780例患者的回顾性登记研究

2019-10-2354
OAAI